[go: up one dir, main page]

WO2004069177A3 - Methodes permettant de moduler une reaction inflammatoire - Google Patents

Methodes permettant de moduler une reaction inflammatoire Download PDF

Info

Publication number
WO2004069177A3
WO2004069177A3 PCT/US2004/002767 US2004002767W WO2004069177A3 WO 2004069177 A3 WO2004069177 A3 WO 2004069177A3 US 2004002767 W US2004002767 W US 2004002767W WO 2004069177 A3 WO2004069177 A3 WO 2004069177A3
Authority
WO
WIPO (PCT)
Prior art keywords
modulating
methods
inflammatory response
wsx
animal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/002767
Other languages
English (en)
Other versions
WO2004069177A2 (fr
Inventor
Christopher Hunter
Alejandro Villarino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2004/002646 external-priority patent/WO2004069173A2/fr
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Priority to MXPA05008131A priority Critical patent/MXPA05008131A/es
Priority to AU2004209967A priority patent/AU2004209967B9/en
Priority to CA2514641A priority patent/CA2514641C/fr
Priority to JP2006503215A priority patent/JP4909069B2/ja
Priority to EP04707360A priority patent/EP1587483A4/fr
Publication of WO2004069177A2 publication Critical patent/WO2004069177A2/fr
Anticipated expiration legal-status Critical
Publication of WO2004069177A3 publication Critical patent/WO2004069177A3/fr
Priority to AU2009203080A priority patent/AU2009203080B9/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des nouvelles méthodes permettant de moduler une réponse immunitaire chez un animal, qui consistent à administrer audit animal une dose efficace d'un agent qui augmente l'activité de l'IL-27R/WSX-1. L'invention concerne en outre des compositions pharmaceutiques comprenant une dose efficace d'un agent qui augmente l'activité de l'IL-27R/WSX-1.
PCT/US2004/002767 2003-01-31 2004-02-02 Methodes permettant de moduler une reaction inflammatoire Ceased WO2004069177A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
MXPA05008131A MXPA05008131A (es) 2003-01-31 2004-02-02 Metodos para la modulacion de una respuesta inflamatoria.
AU2004209967A AU2004209967B9 (en) 2003-01-31 2004-02-02 Methods for modulating an inflammatory response
CA2514641A CA2514641C (fr) 2003-01-31 2004-02-02 Methodes permettant de moduler une reaction inflammatoire
JP2006503215A JP4909069B2 (ja) 2003-01-31 2004-02-02 炎症反応を調節するための方法
EP04707360A EP1587483A4 (fr) 2003-01-31 2004-02-02 Methodes permettant de moduler une reaction inflammatoire
AU2009203080A AU2009203080B9 (en) 2003-01-31 2009-07-29 Methods for Modulating an Inflammatory Response

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US44449403P 2003-01-31 2003-01-31
US60/444,494 2003-01-31
US51907403P 2003-11-10 2003-11-10
US60/519,074 2003-11-10
PCT/US2004/002646 WO2004069173A2 (fr) 2003-01-31 2004-01-30 Procedes pour moduler une reaction inflammatoire
USPCT/US04/02646 2004-01-30

Publications (2)

Publication Number Publication Date
WO2004069177A2 WO2004069177A2 (fr) 2004-08-19
WO2004069177A3 true WO2004069177A3 (fr) 2006-01-12

Family

ID=32851399

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/002767 Ceased WO2004069177A2 (fr) 2003-01-31 2004-02-02 Methodes permettant de moduler une reaction inflammatoire

Country Status (2)

Country Link
MX (1) MXPA05008131A (fr)
WO (1) WO2004069177A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4839434B2 (ja) * 2005-03-14 2011-12-21 千葉県 ｐ２８分子またはその遺伝子を含む医薬製剤
WO2008025031A1 (fr) * 2006-08-25 2008-02-28 Zymogenetics, Inc. traitement de la réaction de greffe contre hôte
WO2008025033A2 (fr) * 2006-08-25 2008-02-28 Zymogenetics, Inc. traitement de l'anémie aplastique
RU2644346C2 (ru) 2011-06-01 2018-02-08 Интрексон Актобиотикс Н.В. Система полицистронной экспрессии для бактерий
AU2017208153B2 (en) 2016-01-14 2021-01-28 Intrexon Actobiotics N.V. Compositions and methods for the treatment of type 1 diabetes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of EP1587483A4 *
SPRECHER C. ET AL: "Cloning and Characterization of a Novel Clas 1 Cytokine Receptor.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS., vol. 246, 1998, pages 82 - 90, XP002174914 *

Also Published As

Publication number Publication date
WO2004069177A2 (fr) 2004-08-19
MXPA05008131A (es) 2005-10-05

Similar Documents

Publication Publication Date Title
WO2004069173A3 (fr) Procedes pour moduler une reaction inflammatoire
WO2006031878A3 (fr) Composés à base d'imidazoquinoline
WO2006069241A3 (fr) Methodes permettant d'ameliorer la sante bucco-dentaire chez les animaux
WO2005004818A3 (fr) Composes heterocycliques et leur utilisation comme agents anticancereux
WO2007109812A3 (fr) Composes de potentialisation immunitaire
EP2592073A3 (fr) Inhibiteurs de protéines tyrosine-phosphatases humaines et leur utilisation
WO2007120528A3 (fr) Inhibiteurs d'adhérence médiée par l'amine oxydase sensible aux semi-carbazides (ssao) et la vap-1 utilisés dans le traitement et la prévention de maladies
WO2006047516A3 (fr) Composes et compositions servant d'inhibiteurs d'activite de recepteur cannabinoide de type 1
WO2006002976A3 (fr) Formulation dietetique contre l'arthrose de chien
WO2005123116A3 (fr) Compositions et procedes pour le traitement ou la prevention de maladie liee a l'oxalate
WO2005003172A3 (fr) Compositions et procedes permettant de reguler l'activite des cellules nk
WO2008148074A3 (fr) Inhibiteurs de mtor et methodes de traitement mettant en œuvre ces inhibiteurs
WO2007070052A3 (fr) Compositions pharmaceutiques et méthodes destinées à traiter ou prévenir une maladie associée à l'oxalate
ZA200705750B (en) Compositions and methods for stabilizing active pharmaceutical ingredients
WO2006012527A8 (fr) Groupes de liaison bivalents et conjugués de ceux-ci
WO2007064885A3 (fr) Compositions, procedes, dispositifs et systemes pour soins buccaux
WO2008087367A3 (fr) Derives de (phenylthiazolyl)-phenyl-propan-1-one et de (phenyloxazodyl)-phenyl-propan-1-one substitues, preparations et utilisations
CA2672094C (fr) Procedes et appareil pour l'identification de matiere dans des donnees de visualisation
WO2007092065A3 (fr) Composés et compositions servant de modulateurs du lxr
WO2006105359A3 (fr) Methodes pour stimuler la pousse des cheveux par administration de proteines bmp
EP2279726A3 (fr) Compositions et méthodes d'utilisation desdites compositions dans l'administration d'agents dans un organe cible protégé par une barrière sanguine
WO2005077122A3 (fr) Composes et compositions convenant comme modulateurs des lxr
WO2008051862A3 (fr) Compositions renforçant l'immunité comprenant du bêta-1,3/1,6-d-glucane et utilisations de celles-ci
WO2006118884A3 (fr) Dispositifs d'administration de medicaments, composants, systemes et methodes associes
WO2004069177A3 (fr) Methodes permettant de moduler une reaction inflammatoire

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/008131

Country of ref document: MX

Ref document number: 2514641

Country of ref document: CA

Ref document number: 2004707360

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006503215

Country of ref document: JP

Ref document number: 2004209967

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2004209967

Country of ref document: AU

Date of ref document: 20040202

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004209967

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004707360

Country of ref document: EP